The mesenchymal stem cells in multiple sclerosis (MSCIMS) trial protocol and baseline cohort characteristics: an open-label pre-test: post-test study with blinded outcome assessments

Background No treatments are currently available that slow, stop, or reverse disease progression in established multiple sclerosis (MS). The Mesenchymal Stem Cells in Multiple Sclerosis (MSCIMS) trial tests the safety and feasibility of treatment with a candidate cell-based therapy, and will inform...

Full description

Saved in:
Bibliographic Details
Published in:Current controlled trials in cardiovascular medicine Vol. 12; no. 1; p. 62
Main Authors: Connick, Peter, Kolappan, Madhan, Patani, Rickie, Scott, Michael A, Crawley, Charles, He, Xiao-Ling, Richardson, Karen, Barber, Kelly, Webber, Daniel J, Wheeler-Kingshott, Claudia AM, Tozer, Daniel J, Samson, Rebecca S, Thomas, David L, Du, Ming-Qing, Luan, Shi L, Michell, Andrew W, Altmann, Daniel R, Thompson, Alan J, Miller, David H, Compston, Alastair, Chandran, Siddharthan
Format: Journal Article
Language:English
Published: London BioMed Central 02.03.2011
BioMed Central Ltd
Springer Nature B.V
BMC
Subjects:
ISSN:1745-6215, 1745-6215
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first